Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-06-07FDA Approved: VILAZODONE HYDROCHLORIDE — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for vilazodone hydrochloride from Accord Healthcare Inc., authorizing a generic version of the antid…
-
FDA approval · 2023-06-07FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for Quetiapine Fumarate by Macleods Pharmaceuticals Limited under ANDA203359.
-
FDA approval · 2023-06-07FDA Approved: VILAZODONE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals, Inc.)
The FDA approved Teva's supplemental application for vilazodone hydrochloride (generic vilazodone) under ANDA 208212.
-
CLINICAL_TRIALS trial_result · 2023-06-07Clinical Trial Update: Inflammation-Induced CNS Glutamate Changes in Depression [Phase 4]
Phase 4 clinical trial investigating inflammation-induced CNS glutamate changes in depression was terminated.
-
FDA approval · 2023-06-07FDA Approved: QUETIAPINE — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for a generic quetiapine product from Macleods Pharmaceuticals Limited.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-06-06Clinical Trial Update: Preventing Depressive Relapse in Pregnant Women With Recurrent Depression [NA]
A completed clinical trial study examining prevention of depressive relapse in pregnant women with recurrent depression; results posted in 2…
-
FDA approval · 2023-06-05FDA Approved: QUETIAPINE — Supplemental Application (Accord Healthcare Inc.)
The FDA approved Accord Healthcare Inc.'s supplemental application for quetiapine (ANDA 202152), granting approval of a generic quetiapine p…
-
CLINICAL_TRIALS trial_result · 2023-06-05Clinical Trial Update: BRITEPath- Phase 2 [NA]
Phase 2 clinical trial update (BRITEPath) completed; results posted in 2023-06-05.
-
CLINICAL_TRIALS trial_result · 2023-06-05Clinical Trial Update: Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression [NA]
A completed clinical trial investigating transcranial near-infrared radiation and cerebral blood flow in individuals with major depressive d…
-
CLINICAL_TRIALS trial_result · 2023-06-02Clinical Trial Update: Standardized Versus Tailored Implementation of Measurement Based Care for Depression [NA]
Completed clinical trial comparing standardized versus tailored measurement-based care for depression; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-06-01Clinical Trial Update: Electroconvulsive Therapy Amplitude Titration [NA]
Clinical trial update reporting completed study on electroconvulsive therapy amplitude titration for major depressive disorder with results …
-
FDA approval · 2023-05-30FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approves a supplemental application for quetiapine fumarate submitted by Unichem Pharmaceuticals (USA), Inc.
-
CLINICAL_TRIALS trial_result · 2023-05-26Clinical Trial Update: Evaluation of a Crowd-Powered Web Platform for Depression and Anxiety [NA]
A completed clinical trial evaluating a crowd-powered web platform for depression and anxiety with results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-05-25Clinical Trial Update: Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults [NA]
A completed clinical trial investigates cranial electrotherapy stimulation for treating Major Depressive Disorder in adults; results posted …
-
CLINICAL_TRIALS trial_result · 2023-05-22Clinical Trial Update: L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults [Phase 4]
Phase 4 trial update evaluating L-DOPA versus placebo for depression and psychomotor slowing in older adults has been terminated with result…
-
CLINICAL_TRIALS trial_result · 2023-05-22Clinical Trial Update: 1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study) [Phase 4]
Phase 4 clinical trial update on 1/2-dopaminergic dysfunction in late-life depression (The D3 Study) has terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2023-05-19Clinical Trial Update: Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment [Phase 4]
Phase 4 pragmatic trial comparing vortioxetine to SSRIs in elderly patients with major depressive disorder; completed.
-
CLINICAL_TRIALS trial_result · 2023-05-19Clinical Trial Update: Text 2 Connect- Texting Intervention for Mental Health Treatment Utilization [NA]
A completed clinical trial evaluating a texting intervention to improve treatment utilization for depression and suicidal ideation.
-
FDA approval · 2023-05-19FDA Approved: AMITRIPTYLINE HYDROCHLORIDE — Original Application (Rising Pharma Holdings, Inc.)
FDA approved Amitriptyline hydrochloride from Rising Pharma Holdings, Inc. under an Original Application (generic) for the treatment of majo…
-
FDA approval · 2023-05-18FDA Approved: VENLAFAXINE HYDROCHLORIDE — Original Application (Granules Pharmaceuticals Inc.)
FDA approved a generic version of venlafaxine hydrochloride from Granules Pharmaceuticals Inc. via an Original Application (ANDA), a generic…
-
CLINICAL_TRIALS trial_result · 2023-05-17Clinical Trial Update: Goal2Quit + NRT Sampling [NA]
Clinical trial update for Goal2Quit with nicotine replacement therapy sampling; study completed with results posted in 2023.
-
CLINICAL_TRIALS research · 2023-05-12Clinical Trial Update: A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health [Phase 4]
A Phase 4 retrospective effectiveness trial evaluated ketamine-assisted psychotherapy in adults with depression and anxiety (and PTSD as lis…
-
FDA approval · 2023-05-11FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for quetiapine fumarate submitted by BluePoint Laboratories. This action approves a modification to …
-
FDA approval · 2023-05-11FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for quetiapine fumarate filed by Sun Pharmaceutical Industries.
-
FDA approval · 2023-05-11FDA Approved: QUETIAPINE EXTENDED RELEASE — Supplemental Application (ACI Healthcare USA, Inc.)
FDA approves a supplemental application for a generic Quetiapine Extended Release product from ACI Healthcare USA, expanding access to the e…